# Subba R. Digumarthy

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/subba-r-digumarthy/

## Facts

| Field | Value |
| --- | --- |
| Citations | 24,689 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 59 |
| i10-index | 164 |
| Last Known Institution | Massachusetts General Hospital |
| OpenAlex ID | https://openalex.org/A5052578824 |
| ORCID iD | https://orcid.org/0000-0003-4041-6716 |
| Works | 565 |

## Researcher papers

Showing 12 of 14.

- [Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors](https://scholariq.org/papers/genotypic-and-histological-evolution-of-lung-cancers-acquiring-resistance-to/)
- [Isolation of rare circulating tumour cells in cancer patients by microchip technology](https://scholariq.org/papers/isolation-of-rare-circulating-tumour-cells-in-cancer-patients-by-microchip/)
- [Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor <i>EML4-ALK</i>](https://scholariq.org/papers/clinical-features-and-outcome-of-patients-with-non-small-cell-lung-cancer-who/)
- [Detection of Mutations in <i>EGFR</i> in Circulating Lung-Cancer Cells](https://scholariq.org/papers/detection-of-mutations-in-i-egfr-i-in-circulating-lung-cancer-cells/)
- [<i>EGFR</i> Mutations and <i>ALK</i> Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis](https://scholariq.org/papers/i-egfr-i-mutations-and-i-alk-i-rearrangements-are-associated-with-low-response/)
- [Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in <i>ALK</i> -Rearranged Lung Cancer](https://scholariq.org/papers/molecular-mechanisms-of-resistance-to-first-and-second-generation-alk-inhibitors/)
- [Heterogeneity Underlies the Emergence of <i>EGFR</i> T790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor](https://scholariq.org/papers/heterogeneity-underlies-the-emergence-of-i-egfr-i-t790-wild-type-clones/)
- [Landscape of Acquired Resistance to Osimertinib in <i>EGFR</i> -Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired <i>RET</i> Fusion](https://scholariq.org/papers/landscape-of-acquired-resistance-to-osimertinib-in-i-egfr-i-mutant-nsclc-and/)
- [Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status](https://scholariq.org/papers/diminished-efficacy-of-programmed-death-ligand-1-inhibition-in-stk11-and-keap1/)
- [Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice](https://scholariq.org/papers/implementing-multiplexed-genotyping-of-non-small-cell-lung-cancers-into-routine/)
- [Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression](https://scholariq.org/papers/outcomes-to-first-line-pembrolizumab-in-patients-with-non-small-cell-lung-cancer/)
- [BIM Expression in Treatment-Naïve Cancers Predicts Responsiveness to Kinase Inhibitors](https://scholariq.org/papers/bim-expression-in-treatment-naive-cancers-predicts-responsiveness-to-kinase/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)

## Researcher university

- [Massachusetts General Hospital](https://scholariq.org/institutions/massachusetts-general-hospital/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.